Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver fibrosis

Florian F. Hildenbrand(University of Zurich), Sena Blümel(University Hospital Zurich), Arnold von Eckardstein(University Hospital of Zurich), Beat Müllhaupt(University Hospital of Zurich), Barbara Illi(Institute of Molecular Biology and Pathology), Stefanie von Felten(University of Zurich), Jacqueline Bachofner(University Hospital Zurich), Joachim C. Mertens(GastroZentrum Hirslanden Zürich), Joanna Gawinecka(University Hospital of Zurich)
BMC Gastroenterology
January 30, 2024
10.1186/s12876-023-03116-4
Cited by 0

Related Papers

Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
|European Heart Journal|2022|1.3k
Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine
|European Heart Journal|2016|830
Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors
|Nature Medicine|2006|339